Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kaori Matsuzaka"'
Autor:
Masatoshi Matsuo, Kazuhiro Noguchi, Jun Taguchi, Takahiro Sakai, Tatsuro Jo, Shizuka Hayashi, Kaori Matsuzaka
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 14, Iss 1, Pp 493-499 (2021)
Case Reports in Oncology, Vol 14, Iss 1, Pp 493-499 (2021)
We present the case of a patient with multiple tyrosine kinase inhibitor (TKI)-refractory chronic phase chronic myeloid leukemia (CP-CML) with a T315I mutation of abl1. Dasatinib, a second-generation TKI, was administered as the initial treatment but
Autor:
Haruna Shioya, Hiroo Tominaga, Kuniko Abe, Kazuto Shigematsu, Tatsuro Jo, Takahiro Sakai, Kaori Matsuzaka, Yohei Kaneko, Shizuka Hayashi, Jun Taguchi, Masatoshi Matsuo
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 13, Iss 3, Pp 1402-1409 (2020)
Case Reports in Oncology, Vol 13, Iss 3, Pp 1402-1409 (2020)
We present the case of a 78-year-old male patient who was diagnosed with anaplastic lymphoma kinase (ALK)-negative, CC chemokine receptor 4 (CCR4)-negative, and CD30-positive anaplastic large cell lymphoma (ALCL). The patient had a past medical histo
Autor:
Masatoshi Matsuo, Tatsuro Jo, Kuniko Abe, Jun Taguchi, Hiroo Tominaga, Ritsuko Kubota-Koketsu, Yohei Kaneko, Shizuka Hayashi, Kazuto Shigematsu, Takahiro Sakai, Kaori Matsuzaka, Haruna Shioya
Publikováno v:
Anticancer Research. 40:5237-5243
Background/aim Adult T-cell leukemia/lymphoma (ATLL) is a relatively refractory CD4-positive peripheral T-cell lymphoma. VCAP-AMP-VECP (mLSG15) is one of the standard chemotherapeutic regimens for patients with aggressive ATLL. Mogamulizumab (moga),
Autor:
Hiroo Tominaga, Yohei Kaneko, Shizuka Hayashi, Haruna Shioya, Takahiro Sakai, Masatoshi Matsuo, Tatsuro Jo, Jun Taguchi, Kaori Matsuzaka
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 13, Iss 2, Pp 990-996 (2020)
Case Reports in Oncology, Vol 13, Iss 2, Pp 990-996 (2020)
This case report is about a patient who suffered from Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia. The blasts were positive for myeloid-lineage markers including CD13 and CD33, as well as B-cell-lineage markers. Minor bcr-abl1